Justine M Kahn1, Theresa H M Keegan2, Li Tao3, Renata Abrahão3,4, Archie Bleyer5, Aaron D Viny6. 1. Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Columbia University Medical Center, New York, New York. 2. Division of Hematology and Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, California. 3. Cancer Prevention Institute of California, Fremont, California. 4. Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom. 5. Department of Radiation Medicine, Oregon Health and Science University, Portland, Oregon. 6. Human Oncology & Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND: Race-based survival in children and adolescents with hematologic malignancies has been a national challenge for decades. Large-scale investigations of age- and race-based survival trends over time in these patients have not previously been reported. The objective of this study was to investigate whether race- and age-related differences in pediatric and adolescent and young adult (AYA) leukemia and lymphoma survival persist and to what extent these differences have changed over time. METHODS: Using the Surveillance, Epidemiology, and End Results program, this study investigated the outcomes of black and white (1975-2012; n = 27,369) and white and Hispanic (1992-2012; n = 20,574) children (0-14 years old) and AYAs (15-39 years old) with acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), and Hodgkin lymphoma (HL). Estimates of 5- and 10-year relative survival were compared over time. RESULTS: Trends showed a convergence of survival for white and black children with ALL but a divergence in survival for AYA patients. Hispanic children and AYAs both suffered inferior outcomes. Trends for AML revealed persistent survival differences between black and white children and suggested worsening disparities for AYAs. Survival trends in HL revealed sustained survival differences between black and white AYA patients, whereas no differences were found in Hispanic and white patient outcomes for AML or HL. CONCLUSIONS: Although survival for children and AYAs with ALL, AML, and HL has improved over the past 4 decades, differences persist between black, white, and Hispanic children and AYAs; survival disparities between black and white children with ALL have been nearly eliminated. Strategies aimed at identifying causality and reducing disparities are warranted. Cancer 2016.
BACKGROUND:Race-based survival in children and adolescents with hematologic malignancies has been a national challenge for decades. Large-scale investigations of age- and race-based survival trends over time in these patients have not previously been reported. The objective of this study was to investigate whether race- and age-related differences in pediatric and adolescent and young adult (AYA) leukemia and lymphoma survival persist and to what extent these differences have changed over time. METHODS: Using the Surveillance, Epidemiology, and End Results program, this study investigated the outcomes of black and white (1975-2012; n = 27,369) and white and Hispanic (1992-2012; n = 20,574) children (0-14 years old) and AYAs (15-39 years old) with acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), and Hodgkin lymphoma (HL). Estimates of 5- and 10-year relative survival were compared over time. RESULTS: Trends showed a convergence of survival for white and black children with ALL but a divergence in survival for AYA patients. Hispanic children and AYAs both suffered inferior outcomes. Trends for AML revealed persistent survival differences between black and white children and suggested worsening disparities for AYAs. Survival trends in HL revealed sustained survival differences between black and white AYA patients, whereas no differences were found in Hispanic and white patient outcomes for AML or HL. CONCLUSIONS: Although survival for children and AYAs with ALL, AML, and HL has improved over the past 4 decades, differences persist between black, white, and Hispanic children and AYAs; survival disparities between black and white children with ALL have been nearly eliminated. Strategies aimed at identifying causality and reducing disparities are warranted. Cancer 2016.
Keywords:
Epidemiology; Surveillance; adolescent; adolescent and young adult (AYA); and End Results (SEER); disparities; leukemia; lymphoma; pediatric; race; survival
Authors: Bassem I Razzouk; Elihu Estey; Stanley Pounds; Shelly Lensing; Sherry Pierce; Mark Brandt; Jeffrey E Rubnitz; Raul C Ribeiro; Michael Rytting; Ching-Hon Pui; Hagop Kantarjian; Sima Jeha Journal: Cancer Date: 2006-06-01 Impact factor: 6.860
Authors: Ching-Hon Pui; Deqing Pei; Alberto S Pappo; Scott C Howard; Cheng Cheng; John T Sandlund; Wayne L Furman; Raul C Ribeiro; Sheri L Spunt; Jeffrey E Rubnitz; Sima Jeha; Melissa M Hudson; Larry E Kun; Thomas E Merchant; Mehmet Kocak; Alberto Broniscer; Monika L Metzger; James R Downing; Wing Leung; William E Evans; Amar Gajjar Journal: J Clin Oncol Date: 2012-04-30 Impact factor: 44.544
Authors: Richard Aplenc; Todd A Alonzo; Robert B Gerbing; Franklin O Smith; Soheil Meshinchi; Julie A Ross; John Perentesis; William G Woods; Beverly J Lange; Stella M Davies Journal: Blood Date: 2006-03-14 Impact factor: 22.113
Authors: Loren Gragert; Mary Eapen; Eric Williams; John Freeman; Stephen Spellman; Robert Baitty; Robert Hartzman; J Douglas Rizzo; Mary Horowitz; Dennis Confer; Martin Maiers Journal: N Engl J Med Date: 2014-07-24 Impact factor: 91.245
Authors: Smita Bhatia; Wendy Landier; Lindsey Hageman; Heeyoung Kim; Yanjun Chen; Kristine R Crews; William E Evans; Bruce Bostrom; Jacqueline Casillas; David S Dickens; Kelly W Maloney; Joseph P Neglia; Yaddanapudi Ravindranath; A Kim Ritchey; F Lennie Wong; Mary V Relling Journal: Blood Date: 2014-05-14 Impact factor: 22.113
Authors: Smita Bhatia; Wendy Landier; Muyun Shangguan; Lindsey Hageman; Alexandra N Schaible; Andrea R Carter; Cara L Hanby; Wendy Leisenring; Yutaka Yasui; Nancy M Kornegay; Leo Mascarenhas; A Kim Ritchey; Jacqueline N Casillas; David S Dickens; Jane Meza; William L Carroll; Mary V Relling; F Lennie Wong Journal: J Clin Oncol Date: 2012-05-07 Impact factor: 44.544
Authors: Elysia M Alvarez; Marcio Malogolowkin; Jeffrey S Hoch; Qian Li; Ann Brunson; Brad H Pollock; Lori Muffly; Ted Wun; Theresa H M Keegan Journal: JCO Oncol Pract Date: 2020-06-11
Authors: Jie Zhang; Zhi-Wei Ye; Danyelle M Townsend; Chanita Hughes-Halbert; Kenneth D Tew Journal: Adv Cancer Res Date: 2019-04-23 Impact factor: 6.242
Authors: Kristie A Blum; Frank G Keller; Sharon Castellino; Anh Phan; Christopher R Flowers Journal: Br J Haematol Date: 2018-08-10 Impact factor: 6.998
Authors: Karine Darbinyan; Aditi Shastri; Anjali Budhathoki; Daniel Helbig; Rose Snyder; Kith Pradhan; Junaid Saleh-Esa; Noah S Kornblum; Adam F Binder; Swati Goel; Murali Janakiram; Olga Derman; Kira Gritsman; Ulrich Steidl; Ira Braunschweig; Amit Verma; Ioannis Mantzaris Journal: Blood Adv Date: 2017-10-26
Authors: Pooja Rao; Joel E Segel; Lisa M McGregor; Eugene J Lengerich; Joseph J Drabick; Barbara Miller Journal: J Adolesc Young Adult Oncol Date: 2019-10-10 Impact factor: 2.223
Authors: Ursula Creutzig; Matthew A Kutny; Ronald Barr; Richard F Schlenk; Raul C Ribeiro Journal: Pediatr Blood Cancer Date: 2018-04-18 Impact factor: 3.167
Authors: Staci D Arnold; Ruta Brazauskas; Naya He; Yimei Li; Matt Hall; Yoshiko Atsuta; Jignesh Dalal; Theresa Hahn; Nandita Khera; Carmem Bonfim; Shahrukh Hashmi; Susan Parsons; William A Wood; Amir Steinberg; César O Freytes; Christopher E Dandoy; David I Marks; Hillard M Lazarus; Hisham Abdel-Azim; Menachem Bitan; Miguel Angel Diaz; Richard F Olsson; Usama Gergis; Adriana Seber; Baldeep Wirk; C Fred LeMaistre; Celalettin Ustun; Christine Duncan; David Rizzieri; David Szwajcer; Franca Fagioli; Haydar Frangoul; Jennifer M Knight; Rammurti T Kamble; Paulette Mehta; Raquel Schears; Prakash Satwani; Michael A Pulsipher; Richard Aplenc; Wael Saber Journal: Biol Blood Marrow Transplant Date: 2020-05-25 Impact factor: 5.742